Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292396 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00292396 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 180 participants.
The verdict
NCT00292396, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.
Interventions
- DRUG placebo
- DRUG Anti IL-12 monoclonal antibody/ABT-874
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00292396
The ClinicalTrials.gov registry entry for NCT00292396 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00292396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00292396 about?
NCT00292396 is a clinical study titled "Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis". The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT00292396?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2005-11. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00292396?
The interventions under investigation include: placebo (DRUG), Anti IL-12 monoclonal antibody/ABT-874 (DRUG).
Who is sponsoring clinical trial NCT00292396?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.